The risk of cholangiocarcinoma in patients with MASLD is not increased compared to the general population

Christina Villard Linnea Widman Ernesto Sparrelid Annika Bergquist Hannes Hagström a Department of Medicine Huddinge,Karolinska Institutet,Stockholm,Swedenb Division of Transplantation Surgery,Karolinska University Hospital,Stockholm,Swedenc Division of Surgery and Oncology,Department of Clinical Science Intervention and Technology,Karolinska University Hospital,Stockholm,Swedend Department of Upper Abdominal Diseases,Karolinska University Hospital,Stockholm,Sweden
DOI: https://doi.org/10.1080/00365521.2024.2412735
2024-10-10
Scandinavian Journal of Gastroenterology
Abstract:Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing in prevalence globally. MASLD is associated with an increased rate of comorbidities, including cardiovascular disease, liver cirrhosis, and hepatocellular carcinoma (HCC). While the link between MASLD and HCC is well known, the potential association with biliary tract cancer, including cholangiocarcinoma (CCA) and gallbladder cancer (GBC), is less certain. To evaluate whether individuals with MASLD are at increased risk of developing CCA compared to the general population, we performed a nationwide cohort study investigating the longitudinal association between MASLD and CCA.
gastroenterology & hepatology
What problem does this paper attempt to address?